The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
The FDA have identified several ingredients that may be connected to the recent reports of individuals with severe respiratory illness in connection with use of electronic smoking products.
Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.
Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
